Signed the strategic cooperation framework agreement with Hangzhou AnRun Pharmaceutical;
Strategic Cooperation Framework Agreement
Fufangqinlan Oral Liquid completed a randomized, double-blind, dose-seeking, multicenter Ⅱ phase A clinical trial on the safety and efficacy of acute upper respiratory tract infection in children
Fufangqinlan Oral Liquid
ZBD1042 (HNC042) completed phase I clinical trial and obtained trial summary report; The results showed good safety tolerability and supported further study